7.3 billion doses of COVID-19 vaccine worldwide, half of which are Chinese vaccines
On October 14, 2021, Nature published a news commentary, pointing out that the Chinese-made new crown vaccine has played a vital role in the global epidemic, but it also faces doubts about the protection time.

A total of about 7.3 billion doses of the new crown vaccine have been vaccinated globally, of which China's new crown vaccine accounts for about half, the most important being Beijing Kexing and Sinopharm Zhongsheng, who received 1.8 billion doses and 1.5 billion doses respectively.

China's domestic vaccination volume exceeds 2.2 billion doses. At the same time, more than 1 billion doses of China's new crown vaccine have been vaccinated in 110 other countries, including Indonesia, Brazil, Pakistan, Turkey, Iran, Philippines, Morocco, Thailand, Argentina, Venezuela, Cambodia, Sri Lanka , Chile, Mexico, Bangladesh, etc.

Summarize
The covid-19 virus is a huge disaster. There are currently 239 million confirmed cases worldwide and 4.87 million deaths. The research and development of vaccines and new drugs has made a huge contribution to epidemic control. Vaccines have controlled the infection rate. Small molecule drugs such as neutralizing antibodies and Merck's Molnupiravir have prevented most of the transition from mild to severe, and greatly reduced the mortality rate.
Looking for chemical products? Let suppliers reach out to you!
2026-06-20
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Which Companies Are Making Covid Vaccines
-
The Indian Variant Vaccine Efficacy is only 10%, and it was abandoned by South Africa
-
Compensation Methods For Adverse Reactions To Vaccines In The Post-Epidemic Period
-
The Johnson & Johnson Vaccine Is Only 72% Effective, Is It An Inferior Vaccine?
-
Research On The Distribution Of The Incubation Period Of COVID-19
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
How Many Covid Vaccines Are Made Per Second?
Recommend Reading
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
This Week's Isopropanol Market Prices Slightly Increased (9.8-9.12) in China
-
Weak Market Trend for Soda Ash in China
-
Geopolitics "Ignites" Energy and Chemical Sector, Maleic Anhydride Surges High
-
Europe’s Chemical Industry Sounds the “Shutdown Alarm”: It’s Not Just a Few Plants at Risk—The Entire Industrial Chain Is Shaking
-
This Week, the Overall DMF Market in China Remains Largely Stable with Slight Weakness (9.5-9.12)